Endoscopic Sleeve Gastroplasty Significantly Reduces Body Mass Index and Metabolic Complications in Obese Patients

Abstract

ESG is a minimally invasive and effective endoscopic weight loss intervention. In addition to sustained total body weight loss up to 24 months, ESG reduced markers of hypertension, diabetes, and hypertriglyceridemia.

Endoscopic bariatric and metabolic therapies: Another tool for the management of diabetes and obesity

“…In the largest multicenter retrospective study conducted to date (n = 248), TBWL with ESG was reported to be 15.2% at 6 months . These results are similar to prior smaller‐scale prospective studies . Long‐term effectiveness of ESG was confirmed at 24 months with a TBWL of 18.6% …”

“…Unlike POSE, ESG does not include suturing the fundus because it is quite difficult to perform in the retroflexed position with this device. Since the first technical feasibility study conducted on four patients by Abu Dayyeh et al was published, many subsequent studies have demonstrated the safety and efficacy of ESG in both weight loss and improvement in metabolic and physiologic parameters in patients with BMI between 30.0 and 40.0 kg/m 2 . In the largest multicenter retrospective study conducted to date (n = 248), TBWL with ESG was reported to be 15.2% at 6 months .…”

“…In addition, ESG has been shown to reduce metabolic complications in obese patients. In a prospective study on 91 patients who underwent ESG, statistically significant reductions in HbA1c, systolic blood pressure, waist circumference, alanine aminotransferase, and serum triglycerides were reported at 12 months after the procedure …”

“…All patients with serious adverse events made full recoveries without invasive surgical intervention . Mild adverse events were not routinely recorded, although one study reported that 38.4% of patients experienced self‐limited nausea and mild abdominal pain lasting <48 hours after the procedure …”

Bariatric Surgery as a Treatment for Metabolic Syndrome

“…45,52 In addition to sustained total bodyweight loss, endoscopic sleeve gastroplasty has been associated with a reduction in hypertension, diabetes and hypertriglyceridemia markers. 45,52 The EndoBarrier is a duodenal bypass sleeve anchored to the duodenal bulb through a nitinol crown with barbs. The sleeve is advanced into the small bowel, allowing undigested food to reach the jejunum and creating a physical barrier between the food and the intestinal wall.…”